Information Provided By: 
Fly News Breaks for February 3, 2016
DHR
Feb 3, 2016 | 09:10 EDT
Noting that Danaher's stock has dropped 12% over the past quarter, Argus says that the company's sales look poised to continue to rise by about 5%. The firm estimates that the company's profits will rise by double digit percentage levels over time. It keeps a $104 price target and Buy rating on the shares.
News For DHR From the Last 2 Days
DHR
Apr 24, 2024 | 09:23 EDT
DHR
Apr 24, 2024 | 07:22 EDT
DHR
Apr 24, 2024 | 06:40 EDT
Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.
DHR
Apr 24, 2024 | 06:32 EDT
DHR
Apr 24, 2024 | 05:28 EDT
Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.
